Onyx Weight Loss review

What it is

Onyx Weight Loss is a telehealth clinic based in Mooresville, North Carolina, founded by Tasha Vangile, FNP-C and Madalyn Vangile, RN, with Stephanie Robison, APRN-CNP on the clinical team. Its menu runs GLP-1 and GLP-1/GIP weight-loss plans (from $228/month and $280/month, with a $99/month microdosing option), a peptides shelf naming NAD⁺, sermorelin, GHK-Cu, glutathione and PT-141, lipotropic and B12 injections, phentermine, hormone replacement including testosterone, sexual health and nutrition coaching. Medication is dispensed through a named partner, Strive Pharmacy.

How it works

Clinician-led and consultation-first: you book a consultation with a nurse practitioner, are evaluated, and medication with any supplies needed ships to your home if a plan is appropriate. The distinguishing feature is scale in the other direction — this is a named team with stated careers rather than an anonymous provider network behind a quiz, and the site names its dispensing pharmacy, which very few competitors do. Nutrition coaching exists as a separate service rather than being bundled into a plan price, which is at least honestly presented. The constraints are structural. Coverage is eight states: North Carolina, Colorado, Maine, Vermont, Virginia, Iowa, New Hampshire and Pennsylvania — a caption on its contact page rather than a structured list, so confirm it. No LegitScript certification is claimed; the credentialing evidence on the site is a local business award. And the site does not publish a baseline bloodwork protocol or say whether labs are included, which matters most for its hormone line. Its GLP-1 pages also never name semaglutide or tirzepatide directly, describing the plans by mechanism instead, and the compounded status is implied by the Strive Pharmacy relationship rather than stated.

Pricing transparency

Sermorelin is $299/month and NAD⁺ is $299/month, each stated on its own product page. Its GLP-1 plans start at $228/month and $280/month with medication and supplies included and a $99/month microdosing option, and those are entry-tier figures with no dose-escalation pricing published — a limitation likely to apply to the peptide line too, so ask whether $299 holds as a provider adjusts your dose. The two peptide figures are the highest in this batch by a clear margin: comparable sermorelin sits between $149 and $195 a month at several national platforms, and comparable NAD⁺ between $149 and $219. What Onyx offers in exchange is a small named care team and a named pharmacy, which is a real thing to buy but is not a price advantage. Labs are not mentioned or priced anywhere, so budget for them separately if your protocol needs monitoring.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Onyx's site does not state the compounded status explicitly — it is implied by its Strive Pharmacy partnership, Strive being a known compounding pharmacy — and compounded preparations are not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, the five-molecule shelf runs across very different tiers. Sermorelin is a GHRH analogue acting on your own pituitary, a real mechanism with thin long-term human outcome data. Injected NAD⁺ has no controlled human outcome trials at all; the oral precursors NR and NMN are the studied forms and what they show is a raised blood NAD⁺ level, a biomarker rather than a benefit. GHK-Cu is a copper-binding tripeptide with a genuinely interesting cell and animal literature on collagen synthesis and wound repair, and essentially no controlled human outcome data behind the claims made for it. Glutathione is in the same position. PT-141 (bremelanotide) is the exception: an FDA-approved drug, but for one narrow indication — generalised hypoactive sexual desire disorder in premenopausal women — so a compounded version prescribed to anyone else is off-label use of an approved molecule. Individual results vary.

Pros and watch-outs

The evidence behind what Onyx Weight Loss prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• GHK-Cu: the copper peptide between real skincare and overclaim

  A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• PT-141 (bremelanotide): the evidence on a research-popular peptide that is actually FDA-approved

  Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.

How Onyx Weight Loss compares

A few alternatives worth a look, depending on what you’re optimizing for.

• NHNuform Health

  Comparing injectable against oral NAD⁺ if you are willing to prepay in kits

  See Nuform Health →
• NHNava Health

  Peptide therapy inside a lab-led integrative practice you can also visit in person

  See Nava Health →
• OHObu Health

  NAD⁺ injections from a platform that names the pharmacies preparing them

  See Obu Health →